Puma Biotechnology Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer. | ImmunoGen ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. | Takeda Takeda Pharmaceutical is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products. | Ascendis Pharma Ascendis Pharma is a biopharmaceutical company that specializes in endocrinology and oncology. | |
Founding Date | Founding Date 2010 | Founding Date 1981 | Founding Date 1781 | Founding Date 2007 |
Type | Type Public | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Los Angeles, US HQ | Locations Waltham, US HQ | Locations Hellerup, DK HQ Heidelberg, DE Palo Alto, US | |
Employees | Employees 27214% decrease | Employees 277161% increase | Employees 49,281 | Employees 879 |
Valuation ($) | Valuation ($) 125.1 m | Valuation ($) 8.7 b | Valuation ($) 45.6 b | Valuation ($) 8.7 b |
Financial | ||||
Revenue (est.) | Revenue (est.) $235.6m (FY, 2023) | Revenue (est.) $108.8m (FY, 2022) | Revenue (est.) ¥4.3t (FY, 2024) | Revenue (est.) €266.7m (FY, 2023) |
Cost of goods | Cost of goods $62.7m (FY, 2023) | Cost of goods $176k (FY, 2022) | Cost of goods ¥698.7b (FY, 2024) | Cost of goods €41.9m (FY, 2023) |
Gross profit | Gross profit $173m (FY, 2023) | Gross profit $108.6m (FY, 2022) | Gross profit ¥3.6t (FY, 2024) | Gross profit €224.8m (FY, 2023) |
Net income | Net income $21.6m (FY, 2023) | Net income ($222.9m) (FY, 2022) | Net income ¥144.2b (FY, 2024) | Net income (€481.4m) (FY, 2023) |
Funding | ||||
Total funding raised | Total funding raised $ 172m | Total funding raised $ 56m | Total funding raised $ 57.8m | Total funding raised $ 85.8m |